FDA OKs expanded use of AstraZeneca’s Brilinta

The FDA approves AstraZeneca’s (NYSE:AZN) blood thinner Brilinta (ticagrelor), combined with aspirin, for reducing the risk of a first heart attack or stroke in high-risk patients with coronary artery disease.

The med was first approved in the U.S. in July 2011 for acute coronary syndrome.

https://seekingalpha.com/news/3578904-fda-oks-expanded-use-of-astrazenecas-brilinta